Rule 1: The presence of a functional group such as "-COOH" or "-OH" in the molecular structure may lead to adverse effects due to its ability to form hydrogen bonds with other molecules in the body.
 
Rule 2: Molecules containing multiple rings or aromatic systems may lead to adverse effects due to their ability to interact with biological receptors.

Rule 3: If the molecular structure contains a charged atom such as sodium or strontium, it may also lead to adverse effects due to its ability to disrupt ionic balance within cells.

Rule 4: The presence of functional groups such as sulfonamide, nitro group or halogenated aromatic rings in a compound may increase its potential for causing adverse effects.

Rule 5: Compounds with high lipophilicity tend to accumulate in lipid-rich tissues like the liver and brain, which can lead to organ damage and other adverse effects.

Rule 6: The size and shape of a compound can also affect its ability to cross cell membranes and reach target sites within the body. 

Rule 7: The presence of functional groups such as carbonyl group (C=O) or amide group (CONH) in a molecule may increase its likelihood of causing adverse effects. 

Rule 8: A molecule containing aromatic rings may also have a higher risk of causing adverse effects due to their ability to form π-π interactions with other molecules. 

Rule 9: The length and complexity of a molecule's structure may also affect its potential for causing adverse effects. 

Rule 10: A molecule containing a nitro group (-NO2) or a sulfonamide group (-SO2NH2), has a high probability of causing adverse effects in general disorders and administration site conditions. 

Rule 11: If the molecular structure contains a halogen atom such as chlorine (Cl), bromine (Br), or iodine (I), then it also has a high probability of causing adverse effects in general disorders and administration site conditions. 

Rule 12: If the molecular structure contains a heterocyclic ring system such as pyridine (-C5H4N), pyrimidine (-C4H4N2), or pyrazine (-C4H4N2), then it has a moderate probability of causing adverse effects in general disorders and administration site conditions. 

Rule 13: If there is a chlorine atom present in the structure, then it may cause adverse effects.

Rule 14: If the molecule contains a nitro group (-NO2), then it may cause adverse effects.

Rule 15: If the molecule contains a sulfonamide group (-SO2NH2), then it may cause adverse effects. 

Rule 16: If a molecule contains a sulfonamide group (-SO2NH-) or a nitro group (-NO2), then it may have the potential to cause adverse effects. 

Rule 17: If a molecule contains a cyano group (-CN) attached to a carbon atom adjacent to a carbonyl group (-C=O), then it may not have the potential to cause adverse effects. 

Rule 18: If a molecule contains a nitrogen-containing ring system, such as a pyridine or pyrimidine ring, then it may have the potential to cause adverse effects. 

Rule 19: If the molecule contains a nitro group (-NO2) or a sulfonamide group (-SO2NH2), then it has a high probability of causing adverse effects.

Rule 20: If the molecule contains a halogen atom, it can enhance its ability to cross cell membranes and interact with biological targets. 

Rule 21: The presence of functional groups such as sulfonyl, carboxyl, or nitro groups in a compound may increase its potential for causing adverse effects. 

Rule 22: A compound containing multiple aromatic rings may have a higher likelihood of causing adverse effects.

Rule 23: A compound with a molecular weight greater than 500 Daltons may have a lower likelihood of being absorbed into the body and may have a reduced potential for causing adverse effects.

Rule 24: The presence of functional groups such as sulfonyl, nitro, and carboxylic acid may increase the likelihood of causing adverse effects in a molecule. 

Rule 25: A molecule containing multiple rings or aromatic systems may also have a higher risk of causing adverse effects due to their ability to bind strongly to proteins and enzymes. 

Rule 26: The molecular weight and hydrophobicity of a compound can affect its absorption, distribution, metabolism, excretion, and toxicity (ADMET) profile. 

Rule 27: If the molecular structure contains a sulfonyl group (-SO2NH-) or a nitro group (-NO2), then it may have potential side effects on the human body. 

Rule 28: If there is a presence of functional group like carbonyl or carboxylic acid in the structure of the molecule, then it may have potential for causing adverse effects.

Rule 29: If the molecular structure contains a nitrogen atom bonded to other atoms such as carbon and hydrogen, then it may also have potential for causing adverse effects.

Rule 30: If the molecular structure contains halogen atoms such as chlorine or fluorine, then it may increase its ability to cross cell membranes and potentially cause adverse effects. 

Rule 31: If there is a presence of any functional group like "-COOH" or "-OH" in the structure of the molecule, then it may lead to adverse effects on the body. 

Rule 32: If the molecule contains a nitrogen atom bonded to a carbon atom, then it may lead to adverse effects if it is part of a ring structure. 

Rule 33: If there exists a nitro group (-NO2) in the structure of a molecule, then it may cause adverse effects such as general disorders and administration site conditions. 

Rule 34: The presence of a Gd+3 in the molecular structure indicates potential toxicity. 

Rule 35: The presence of fluorine atoms in the molecular structure may increase potential adverse effects due to enhanced lipophilicity.

Rule 36: The presence of negatively charged functional groups such as carboxylate or phosphate groups in the molecular structure increases water solubility making them more likely to interact with proteins and other biomolecules potentially leading to toxic effects. 

Rule 37: If a compound contains a sulfonamide group (-SO2NH-) or a nitro group (-NO2), it may have potential side effects on the human body. 

Rule 38: If the molecular weight of a compound is high, it may indicate that the compound has a larger size and more complex structure, which could potentially increase its toxicity. 

Rule 39: The presence of certain atoms or bonds in a molecule may also affect its potential for causing adverse effects.

Rule 40: If a compound contains a sulfonamide group (-SO2NH-) or a nitro group (-NO2), then it may have the potential to cause adverse effects on the body.

Rule 41: The presence of certain functional groups in a molecule may increase its likelihood of causing adverse effects.

Rule 42: The structure of a molecule plays a crucial role in determining its potential toxicity.

Rule 43: The size and shape of a molecule can also affect its ability to cause adverse effects. 

Rule 44: If the molecular structure contains a sulfonamide group (-SO2NH-) or a nitro group (-NO2), then it may have the potential to cause adverse effects in the body.

Rule 45: If there is a presence of functional group like "-COOH" or "-OH" in the structure of the molecule, then it may lead to adverse effects. 

Rule 46: If the molecular weight of a compound is high, it may indicate that the compound has a larger size and more complex structure, which could potentially increase its toxicity. 

Rule
Rule 1: Molecules with functional groups like a carbonyl or carboxylic acid group can potentially cause adverse effects related to general disorders and administration site conditions.
Rule 2: Complex molecules containing multiple rings or aromatic systems may increase the potential for similar side-effects due to their increased molecular weight and surface area.
Rule 3: The presence of a chlorine atom attached to a carbon chain in a molecule might increase its lipophilicity, facilitating penetration through cell membranes leading to potential toxic effects.
Rule 4: Molecules containing a sulfonamide group (-SO2NH-) have the potential to cause adverse effects.
Rule 5: Molecules containing a fluorine atom bonded to a carbon atom may also potentially cause adverse effects.
Rule 6: Molecules containing a nitro group (-NO2) may have the potential to cause adverse effects related to skin and subcutaneous tissue disorders.
Rule 7: The presence of nitro group (-NO2) in the molecular structure, may lead to adverse effects.
Rule 8: Aromatic rings within the molecular structure may contribute towards causing adverse effects.
Rule 9: Presence of a sulfonyl group (-SO2R) or a carbonyl group (-COR) in the molecular structure may increase the likelihood of adverse effects. 
Rule 10: The presence of functional groups such as nitro groups or halogen groups in a compound can increase its potential to cause adverse effects.
Rule 11: The presence of an aromatic ring can cause adverse effects due to the disruptive nature of their interaction with biological molecules.
Rule 12: High molecular weight or complex structures can increase a compound's risk of causing adverse effects due to increased potential of non-specific interactions with other biomolecules.
Rule 13: The presence of a cyano group (-CN) may indicate potential side effects.
Rule 14: A carbonyl group (-C=O) adjacent to a nitrogen atom may increase the likelihood of causing adverse effects.
Rule 15: Molecules containing a five-membered ring structure with two double bonds and one oxygen atom can potentially cause adverse effects related to general disorders and administration site.
Rule 16: A presence of sulfonamide group (-SO2NH-) or nitro group (-NO2) in a molecule may lead to side effects related to general disorders and administration site conditions.
Rule 17: A compound containing a carboxylic acid group (-COOH) attached to an aromatic ring may potentially cause side effects related to general disorders and administration site conditions.
Rule 18: A presence of a guanidine group (-C(=NH)NH2) may lead to side effects related to general disorders and administration site conditions.
Rule 19: A presence of a halogen atom in the molecular structure may increase the potential for causing adverse effects.
Rule 20: The presence of functional groups such as sulfonamide, nitro group or carboxylic acid group in a molecule's structure may increase its ability to cause adverse effects.
Rule 21: Molecules containing a sulfonamide group (-SO2NH-) or phosphate group (-OPO3H2) have potential to cause adverse effects.
Rule 22: Nitro groups (-NO2) present in the molecular structure can contribute to adverse effects.
Rule 23: A presence of benzene ring in the molecular structure can cause adverse effects.
Rule 24: Functional groups such as nitro group or sulfonamide in a molecule may increase the likelihood of causing side effects.
Rule 25: A molecular weight over 500 Daltons may increase the likelihood of causing adverse effects.
Rule 26: Multiple rings present in the structure of a compound may heighten the likelihood of causing adverse effects.
Rule 27: Presence of functional groups like sulfonyl, carbonyl and nitro groups in a compound raises the likelihood of causing adverse effects.
Rule 28: Multiple ring structures such as aromatic systems increase the compound's chances to cause adverse effects because of their increased lipophilicity and membrane permeability.
Rule 29: High molecular weight and complex structure can lead to compounds being less soluble in water and accumulating in tissues, leading to toxicity. 
Rule 30: The presence of iodine or boron atoms or a carbonyl group in a molecule may suggest the potential presence of side effects.
